Recent News

• 02.09.2026 - 8-K - Current report
• 02.09.2026 - Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
• 02.04.2026 - CORRESP - Correspondence
• 02.04.2026 - UPLOAD - SEC-generated letter
• 02.02.2026 - Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
• 01.29.2026 - 4 - Statement of changes in beneficial ownership of securities
• 01.28.2026 - DEF 14A - Definitive proxy statements
• 01.27.2026 - Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
• 01.12.2026 - S-8 - Securities to be offered to employees in employee benefit plans
• 01.12.2026 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Recent Filings

• 01.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.28.2026 - DEF 14A Other definitive proxy statements
• 01.12.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 01.12.2026 - S-8 Securities to be offered to employees in employee benefit plans